XML 16 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Income (Loss) - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Net revenues $ 3,661 $ 3,661
Cost of sales 2,079 1,921
Gross profit 1,582 1,740
Research and development expenses 234 225
Selling and marketing expenses 546 584
General and administrative expenses 296 296
Intangible assets impairments 178 149
Other assets impairments, restructuring and other items 96 128
Legal settlements and loss contingencies 233 1,124
Other income (2) (52)
Operating income (loss) 2 (713)
Financial expenses, net 260 258
Income (loss) before income taxes (258) (971)
Income taxes (benefit) (19) 2
Share in (profits) losses of associated companies, net   (21)
Net income (loss) (238) (952)
Net income (loss) attributable to non-controlling interests (33) 3
Net income (loss) attributable to Teva $ (205) $ (955)
Earnings (loss) per share attributable to ordinary shareholders:    
Basic $ (0.18) $ (0.86)
Diluted $ (0.18) $ (0.86)
Weighted average number of shares (in millions):    
Basic 1,115 1,107
Diluted 1,115 1,107